“…Thus, the effects of GRK2 on heart function seem to depend both on its expression level and on pathophysiological context. Moreover, altered GRK2 levels and functionality have been found in patient samples and/or in animal models of relevant pathological situations such as HF, hypertension, obesity and insulin resistance‐related situations, nonalcoholic fatty liver disease, pain, inflammation, and some types of cancer, where anomalous GRK2 dosage or activity appears to contribute to disease progression via cell type and context‐specific molecular mechanisms (Cannavo et al, ; Cruces‐Sande et al, ; Gurevich, Gainetdinov, & Gurevich, ; Hullmann, Traynham, Coleman, & Koch, ; Mayor Jr. et al, ; Mushegian, Gurevich, & Gurevich, ; Nogues et al, ; Penela, Nogues, & Mayor Jr., ; Wang, Gu, Eijkelkamp, Heijnen, & Kavelaars, ).…”